Prof. Dr. Ozan Cem Güler

Prof. Dr. Ozan Cem Güler

Radyasyon Onkolojisi

Değerlendir Randevu
0 Değerlendirme
0 Çalışma adresi
Yeni Henüz puan yok

Prof. Dr. Ozan Cem Güler

Bölüm: Radyasyon Onkolojisi

Adresler (0)

Bu uzmana ait bir klinik bulunmamaktadır.

Prof. Dr. Ozan Cem Güler Hakkında

Prof. Dr. Ozan Cem Güler Kimdir?

Diploma Aldığı Kurum

  • GÜLHANE ASKERİ TIP AKADEMİSİ

Eğitimler

  • 2001 – 2007 Lisans Gülhane Askeri Tıp Akademisi (GATA) - ANKARA
  • 2007 – 2008 Tabip Teğmen TCG Sokullu Mehmet Paşa - İSTANBUL ,Dz Harp Ok.
  • 2008 – 2010 Tabip Üsteğmen TCG Cezayirli Gazi Hasan Paşa – İSTANBUL , Dz Harp Ok.
  • 2011 - 2015 Araş. Görev. Başkent Üniversitesi Radyasyon Onkolojisi – ADANA
  • 2015 - 2017 Uzm. Dr. KTÜ Radyasyon Onkolojisi - TRABZON
  • Nisan- Mayıs- Haziran 2016 Universitair Ziekenhuis Brussel / BELGIUM (Observer)
  • 2017 - 2019 Uzm. Dr. Başkent Üniversitesi Radyasyon Onkolojisi – ADANA
  • 2019 - Doç. Dr. Başkent Üniversitesi Radyasyon Onkolojisi – ADANA

Ödüller

  • 2013 En İyi Sözel Bildiri:
  • Yazarlar: Erkan Topkan, Cem Parlak , Ozan Cem Gu?ler, Cem Önal, Uğur Selek.
  • Çalışma: Evre IIIB Küçük Hücreli Dışı Akciğer Kanseri Tanısıyla Eşzamanlı Kemoradyoterapi Uygulanan Hastalarda Uzun Kemoradyoterapi Süresi Kötü Prognozla İlişkilidir.
  • Tümünü Göster

Yayınlar

  • Guler OC, Yuce Sari S, Duru Birgi S, Bahadir M, Yildiz F, Onal C.: Definitive chemoradiotherapy in elderly cervical cancer patients: A multi-instutional analysis. Int J Gynecol Cancer (2017) doi: 10.1097/IGC.0000000000001029.
  • Guler OC, Engels B, Onal C, Everaert H, Van den Begin R, Gevaert T, de Ridder M.: The feasibility of prostate-specific membrane antigen positron emission tomography(PSMA PET/CT)-guided radiotherapy in oligometastatic prostate cancer patients. Clin Transl Oncol. (2017) doi: 10.1007/s12094-017-1736-9.
  • Guler OC, Torun N, Yıldırım BA, Onal C: Pretreatment metabolic tumor volume and total lesion glycolysis are not independent prognosticators for locally advanced cervical cancer patients treated with chemoradiotherapy. Br J Radiol. (2018)
  • Guler OC, Onal C, Acibuci I.: Effects of bladder distension on dose distribution of vaginal vault brachytherapy in patients with endometrial cancer. J Contemp Brachytherapy. (2015) doi: 10.5114/jcb.2014.47868.
  • Guler OC, Yıldırım BA, Onal C, Topkan E: Retrospective comparison of standard and escalated doses of radiotherapy in newly diagnosed glioblastome multiforme patients treated with concurrent and adjuvant temozolomide. Indian Journal of Cancer. (2018)
  • Guler OC, Oymak E, Hurmuz P, Yavas G, Tilki B, Yavas C, Ozyigit G, Onal C. Treatment Outcomes of Stereotactic Body Radiotherapy in Patients with Synchronous and Metachronous Oligometastatic Renal Cell Carcinoma. Urol Int. (2022) doi: 10.1159/000527287.
  • Guler OC, Oymak E, Yazici G, Akagunduz OO, Cetinayak O, Erpolat P, Aksoy A, Duzova M, Yildirim BA, Kurt M, Canyilmaz E, Yavas G, Akyurek S, Oksuz DC, Saglam EK, Celik OK, Ozyar E, Cengiz M, Onal C. Multi-institutional analysis of cervical esophageal carcinoma patients treated with definitive chemoradiotherapy: TROD 01-005 study. Oncol Res. (2023) doi: 10.32604/or.2023.028840.
  • Onal C, Guler OC, Akkus Yildirim B.: Prognostic use of pretreatment hematologic parameters in patients receiving definitive chemoradiotherapy for cervical cancer. Int J Gynecol Cancer. (2016) doi: 10.1097/IGC.0000000000000741.
  • Onal C, Guler OC, Akkus Yildirim B.: Treatment outcomes of breast cancer liver metastasis treated with stereotactic body radiotherapy. The Breast (2018)
  • Onal C, Guler OC, Reyhan M, Yapar AF.: Prognostic value of 18F-fluorodeoxyglucose uptake in pelvic lymph nodes in patients wıth cervical cancer treated with definitive chemoradiotherapy. Gynecol Oncol. 2015 Apr;137(1):40-6. doi: 10.1016/j.ygyno.2015.01.542. Epub 2015 Jan 29.
  • Onal C, Guler OC, Torun N, Oymak E, Reyhan M.: The Significance of Metabolic Response to Neoadjuvant Androgen Deprivation Therapy Detected With [68Ga]Ga-PSMA-11-PET/CT in High-Risk Prostate Cancer Patients Treated With Definitive Radiotherapy. Eur J Nucl Med Mol Imaging (in press).
  • Yuksel Simsek S, Guler OC, Dogan Durdag G, Yüce Sarı S, Gultekin M, Yıldız F, Celik h, Erbay G, Onal HC. The clinical outcomes of ovarian cancer in patients with brain metastasis. Eur. J. Gynaecol. Oncol. 2021
  • Oymak E, Guler OC, Onal C.: Significance of liver metastasis volume in breast cancer patients treated with stereotactic body radiotherapy. Strahlenther Onkol. 2021 Sep 3. doi: 10.1007/s00066-021-01845-7.
  • Gultekin M , Guler OC, Sari SY, Yildirim BA, Onal C, Celik H, Yuce K, Ayhan A, Arik Z, Kose F, Altundag O, Mustafayev TZ, Atalar B, Bolukbasi Y, Yildiz F. Multi-institutional Validation of the ESMO-ESGO-ESTRO Consensus Conference Risk Grouping in Turkish Endometrial Cancer Patients Treated With Comprehensive Surgical Staging. J Obstet Gynaecol. 2020 Apr 29;1-7
  • Yuce Sari S, Guler OC, Gultekin M, Akkus Yildirim B, Onal C, Ozyigit G, Yildiz F, Radiotherapy After Skin-Sparing Mastectomy and Implant-Based Breast Reconstruction. Clin Breast Cancer 19 (5), e611-e616 Oct 2019
  • Topkan E, Guler OC, Özdemir Y: Definitive concurrent chemoradiotherapy outcomes in Stage IIIB nonsmall cell lung cancer patients younger than 45 years: A retrospective analysis of 145 patients. J Cancer Res Ther. 2020 Jul-Sep;16(4):757-763.
  • Yildirim BA, Guler OC, Kose F, Onal C. The prognostic value of haematologic parameter changes during treatment in cervical cancer patients treated with definitive chemoradiotherapy. J Obstet Gynaecol . 2019 Jul;39(5):695-701.
  • Kandaz M, Guler OC, Yoney A: The effect of chemoradiotherapy at gastric cancer on pancreatic enzymes and pancreas volume. International Journal of Hematology and Oncology 2017, 27(1), 29-36
  • Onal C, Guler OC, Dolek Y.: The impact of air pockets around the vaginal cylinder on vaginal vault brachytherapy. Br J Radiol. 2015 Mar;88(1047):20140694. doi: 10.1259/bjr.20140694. Epub 2015 Jan 6.
  • Onal C, Guler OC, Reyhan M, Yapar AF.: Long-term outcomes of cervical cancer patients with complete metabolic response after definitive chemoradiotherapy. J Gynecol Oncol. 2021 Sep;32(5):e74. doi: 10.3802/jgo.2021.32.e74
  • Onal C, Guler OC, Torun N, Reyhan M.: Long-term assessment of clinical parameters and positron emission tomography parameters in predicting recurrence in cervical cancer patients receiving definitive chemoradiotherapy. Nucl Med Commun (2023).
  • Yuce Sari S, Guler OC, Gultekin M, Onal H.C., Yildiz F.: Adjuvant Small Pelvic Radiotherapy in Patients with Cervical Cancer Having Intermediate Risk Factors Only - Is It Sufficient. Oncol Res Treat. 2017 Aug 21;40(9):523-527. doi: 10.1159/000476037.
  • Onal C, Guler OC, Dolek Y, Erbay G.: Uterine perforation during three-dimensional image-guided brachytherapy in cervical cancer patients: Baskent University experience. Int J Gynecol Cancer. 2014 Feb;24(2):346-51.
  • Onal C, Guler OC, Hurmuz P, Yavas G, Tilki B, Oymak E, Yavas C, Ozyigit G.:Bone only oligometastatic renal cell carcinoma patients treated with stereotactic body radiotherapy: A multi-institutional study. Strahlenther Onkol. 2022 Oct;198(10):940-948. doi: 10.1007/s00066-022-01962-x. Epub 2022 Jun 13.
  • Onal C, Guler OC, Torun N, Reyhan M, Yapar AF. The Effect of Androgen Deprivation Therapy on 68 Ga-PSMA Tracer Uptake in Non-Metastatic Prostate Cancer Patients. Eur J Nucl Med Mol Imaging 2019
  • Kandaz M, Güler OC, Yazar U, Canyilmaz E, Yöney A. Whole brain radiotherapy plus conventional boost in Non-Small Cell Lung Cancer Patients with brain metastasis: a retrospective analysis of overall survival. Turk Neurosurg. 2018 Jul 13. doi: 10.5137/1019-5149.JTN.22896-18.3.
  • Onal C, Oymak E, Guler OC, Tilki B, Yavas G, Hurmuz P, Yavas C, Ozyigit G. Stereotactic body radiotherapy and tyrosine kinase inhibitors in patients with oligometastatic renal cell carcinoma: a multi-institutional study. Strahlenther Onkol. 2022 Nov 30. doi: 10.1007/s00066-022-02026-w.
  • Oymak E, Guler OC, Onal C. Prognostic significance of albumin and globulin levels in cervical cancer patients treated with chemoradiotherapy. Int J Gynecol Cancer. 2022 Nov 10;ijgc-2022-003768.
  • Onal C, Erbay G, Guler OC, Oymak E.The prognostic value of mean apparent diffusion coefficient measured with diffusion-weighted magnetic resonance imaging in patients with prostate cancer treated with definitive radiotherapy. Radiother Oncol. 2022 Jun 23;S0167-8140(22)04172-X. doi: 10.1016/j.radonc.2022.06.011.
  • Onal C, Guler OC, Hurmuz P, Yavas G, Tilki B, Oymak E, Yavas C, Ozyigit G. Bone-only oligometastatic renal cell carcinoma patients treated with stereotactic body radiotherapy: a multi-institutional study. Strahlenther Onkol. 2022 Jun 13. doi: 10.1007/s00066-022-01962-x.
  • Onal C, Hurmuz P, Guler OC, Yavas G, Tilki B, Oymak E, Yavas C, Ozyigit G.The role of stereoractic body radiotherapy in switching systemic therapy for patients with extracranial oligometastatic renal cell carcinoma. Clin Transl Oncol. 2022 Feb 4. doi: 10.1007/s12094-022-02793
  • Yıldırım BA, Torun N, Guler OC, Onal C: Prognostic value of metabolic tumor volume and total lesion glycolysis in esophageal carcinoma patients treated with definitive chemoradiotherapy. Nucl Med Commun. 2018
  • Onal C, Findikcioglu A, Guler OC, Reyhan M.: The use of 18F-FDG positron emission tomography to detect mediastinal lymph nodes in metastatic breast cancer. Breast 2020 Dec;54:197-202. doi: 10.1016/j.breast.2020.10.011.
  • Onal C, Yildirim BA, Guler OC, Mertsoylu H: The Utility of Pretreatment and Posttreatment Lymphopenia in Cervical Squamous Cell Carcinoma Patients Treated With Definitive Chemoradiotherapy. Int J Gynecol Cancer. 2018 Oct;28(8):1553-1559. doi: 10.1097/IGC.0000000000001345.
  • Kandaz M, Bahat Z, Guler OC, Canyılmaz E, Melikoglu M, Yoney A: Radiotherapy in the management of classic Kaposi's sarcoma: A single institution experience from Northeast Turkey. Dermatol Ther. 2018 Apr 6:e12605. doi: 10.1111/dth.12605.
  • Onal C, Cengiz M, Guler OC, Dolek Y, Ozkok S.: The role of delineation education programs for improving interobserver variability in target volume delineation in gastric cancer. Br J Radiol. (2017) doi: 10.1259/bjr.20160826.
  • Onal C, Torun N, Guler OC, Yildirim BA.: Prognostic value of metabolic response measured by 18-FDG Positron emission tomography in oesophageal cancer patıents treated with definitive chemoradiotherapy. Nucl Med Commun. 2016 Dec;37(12):1282-1289.
  • Onal C, Erbay G, Guler OC: Treatment response evaluation using the mean apparent diffusion coefficient in cervical cancer patients treated with definitive chemoradiotherapy. J Magn Reson Imaging. 2016 Feb 27. doi: 10.1002/jmri.25215.
  • Yildirim BA, Ozdemir Y, Guler OC, Topkan E: High Prognostic Nutritional Index Relates with Enhanced Survival in Rectal Cancer Patients Treated with Neoadjuvant Chemoradiotherapy. Wulfenia journal, 2016; 23(4)
  • Parlak C, Mertsoylu H, Güler OC, Onal C, Topkan E.: Definitive chemoradiation therapy following surgical resection or radiosurgery plus whole-brain radiation therapy in non-small cell lung cancer patients with synchronous solitary brain metastasis: a curative approach. Int J Radiat Oncol Biol Phys. 2014 Mar 15;88(4):885-91. doi: 10.1016/j.ijrobp.2013.12.017. Epub 2014 Feb 1.
  • Topkan E, Yildirim B.A, Guler OC, ParlakC, PehlivanB, SelekU: Safety and palliative efficacy of single-dose 8-Gy reirradiation for painful local failure in patients with stage IV non-small cell lung cancer previously treated with radical chemoradiation therapy.Int J Radiat Biol. 2015;91(4):774-80.
  • Onal C, Reyhan M, Guler OC, Yapar AF. : Treatment outcomes of patients with cervical cancer with complete metabolic responses after definitive chemoradiotherapy. Eur J Nucl Med Mol Imaging. 2014 Jul;41(7):1336-42. doi: 10.1007/s00259-014-2719-5. Epub 2014 Feb 22.
  • Onal C, Efe E, Guler OC, Yildirim BA. Dosimetric Comparison of Sequential Versus Simultaneous-integrated Boost in Early-stage Breast Cancer Patients Treated With Breast-conserving Surgery. In Vivo 33 (6), 2181-2189 Nov-Dec 2019
  • Ozdemir Y, Torun N, Guler OC, Yıldırım BA, Besen AA, Yetisken AG, Onal C, Topkan E. Local control and vertebral compression fractures following stereotactic body radiotherapy for spine metastases. Journal of Bone Oncology.
  • Topkan E, Ozdemir Y, Guler OC, Kucuk A, Besen AA, Mertsoylu H, Sezen D, Akdemir EY, Sezer A, Bolukbasi Y, Pehlivan B, Selek U. Comparison of Involved Field Radiotherapy versus Elective Nodal Irradiation in Stage IIIB/C Non-Small-Cell Lung Carcinoma Patients Treated with Concurrent Chemoradiotherapy: A Propensity Score Matching Study. J Oncol. 2020 Sep 4;2020:7083149.
  • Yildirim BA, Dolek Y, Guler OC, Arslan G, Onal C.: Dosimetric comparison of vaginal vault brachytherapy vs applicator-guided stereotactic body radiotherapy with volumetric modulated arc therapy and helical tomotherapy for endometrium cancer patients. Med Dosim. 2018 Dec 11. pii: S0958-3947(18)30136-5. doi: 10.1016/j.meddos.2018.11.005. [Epub ahead of print]
  • Erbay G, Onal C, Guler OC, Karadeli E, Koc Z.: Correlation of clinical risk factors with Diffusion-Weighted Magnetic Resonance Images in prostate cancer patients treated with definitive radiotherapy. International Journal of Hematology and Oncology 2015, Vol 25, Num 2 Page(s):88-97.
  • Kandaz M, Bahat Z, Guler OC, Canyılmaz E, Yazar U, Yöney A: Outcomes of Treatment for Glioblastoma Multiforme in Adult Patients: A Single Institution Experience from the Eastern Black Sea Region of Turkey. International Journal of Hematology and Oncology 2017 doi:10.4999
  • Onal C, Ozyigit G, Guler OC, Hurmuz P, Torun N, Tuncel M, Dolek Y, Yedekci Y, Oymak E, Tilki B, Akyol F.: Role of 68-Ga-PSMA-PET/CT in pelvic radiotherapy field definitions for lymph node coverage in prostate cancer patients. Radiother Oncol. 2020 Aug 28;151:222-227. doi: 10.1016/j.radonc.2020.08.021.
  • Sezer A, Akkus B, Guler OC, Onal HC, Sumbul AT.: Concurrent versus sandwich treatment in adjuvant treatment in high risk operated gastric cancer: A single center experience. J BUON . Sep-Oct 2020;25(5):2341-2349.
  • Erbay G, Onal C, Karadeli E, Guler OC, Arica S, Koc Z.: Predicting tumor recurrence in patients with cervical carcinoma treated with definitive chemoradiotherapy: Value of quantitative histogram analysis on diffusion-weighted MR images. Acta Radiol. 2016 Jul 20. pii: 0284185116656492.
  • Onal C, Yuce Sari S, Yavas G, Guler OC, Yigit E, Oymak E, Gultekin M, Yildiz F.: The impact of lymph node ratio in patients with stage IIIC endometrial carcinoma treated with postoperative radiotherapy. Future Oncol. 2021 Aug 6. doi: 10.2217/fon-2020-1308.
  • Onal C, Ozyigit G, Oymak E, Guler OC, Hurmuz P, Tilki B, Reyhan M, Tuncel M, Akyol F.: Clinical parameters and nomograms for predicting lymph node metastasis detected with 68Ga-PSMA-PET/CT in prostate cancer patients candidate to definitive radiotherapy. Prostate. 2021 May 5. doi: 10.1002/pros.24142.
  • Kose F, Alemdaroglu S, Mertsoylu H, Besen AA, Guler OC, Simsek SY, Erbay G, Onal C, Celik H. Half-dose bevacizumab experience in relapsed ovarian cancer patients in Turkey due to formal regulations: similar effectiveness with lower rate of hypertension. J BUON . Jul-Aug 2020;25(4):1928-1934.
  • Kose F, Alemdaroglu S, Besen AA, Guler OC, Mertsoylu H, Onal C, Celik H. Clinical characteristics of relapsed ovarian cancer patients with striking response to the bevacizumab at first relapse. Eur. J. Gynaecol. Oncol. 2020, Vol. 41 Issue (6): 989-995
  • Onal C, Torun N, Akyol F, Guler OC, Hurmuz P, Akkus Yildirim B, Caglar M, Reyhan M, Ozyigit G.: Integration of 68Ga-PSMA-PET/CT in radiotherapy planning for prostate cancer patients. Clinical Nuclear Medicine 2019
  • Onal C, Sonmez S, Erbay G, Guler OC, Arslan G.: Simultaneous integrated boost to intraprostatic lesions using different energy levels of intensity-modulated radiotherapy and volumetric-arc therapy. Br J Radiol. 2014 Feb;87(1034):20130617. doi: 10.1259/bjr.20130617. Epub 2013 Dec 6.
  • Onal C, Ozyigit G, Oymak E, Guler OC, Tilki B, Hurmuz P, Akyol F.: Stereotactic radiotherapy to oligoprogressive lesion detected with 68Ga-PSMA-PET/CT in castration resistant prostate cancer patients. Eur J Nucl Med Mol Imaging. 2021 Oct;48(11):3683-3692. doi: 10.1007/s00259-021-05298-z. Epub 2021
  • Topkan E, Parlak C, Topuk S, Guler OC, Selek U.: Outcomes of aggressive concurrent radiochemotherapy in highly selected septuagenarians with stage IIIB non-small cell lung carcinoma: Retrospective analysis of 89 patients. Lung Cancer. 2013 May 29. S0169-5002(13)00214-6
  • Onal C, Reyhan M, Parlak C, Guler OC, Oymak E.: Prognostic value of pretreatment FDG uptake in cervical cancer patients treated with definitive chemoradiotherapy. Int J Gynecol Cancer. 2013 Jul;23(6):1104-10
  • Akkus Yildirim B, Onal C, Erbay G, Guler OC, Karadeli E, Reyhan M, Koc Z.: Prognostic values of ADCmean and SUVmax of the primary tumor in cervical cancer patients treated with definitive chemoradiotherapy. Journal of Obstetrics and Gynaecology 2018
  • Topkan E, Selek U, Ozdemir Y, Yildirim BA, Guler OC, Mertsoylu H, Hahn SM. Chemoradiotherapy-induced hemoglobin nadir values and survival in patients with stage III non-small cell lung cancer. Lung Cancer 121 (2018) 30–36
  • Topkan E, Selek U, Ozdemir Y, Yildirim BA, Guler OC, Ciner F, Besen AA, Findikcioglu A, Ozyilkan O: Incidence and Impact of Pretreatment Tumor Cavitation on Survival Outcomes of Stage III Squamous Cell Lung Cancer Patients Treated With Radical Concurrent Chemoradiation Therapy. Int J Radiat Oncol Biol Phys. 2018 Aug 1;101(5):1123-1132.
  • Haciislamoglu E, Gungor G, Aydin G, Canyilmaz E, Guler OC, Zengin AY, Yenice KM. Estimation of secondary cancer risk after radiotherapy in high-risk prostate cancer patients with pelvic irradiation. J Appl Clin Med Phys. 2020 Sep;21(9):82-89.
  • Topkan E, Selek U, Ozdemir Y, Yildirim BA, Guler OC, Ciner F, Mertsoylu H, Tufan K. Prognostic value of the Glasgow Prognostic Score for glioblastoma multiforme patients treated with radiotherapy and temozolomide. Journal of Neuro-Oncology 2018
  • Topkan E, Selek U, Ozdemir Y, Besen AA, Guler OC, Yildirim BA, Mertsoylu H, Findikcioglu A, Ozyilkan O, Pehlivan B. : Risk Factors for Fatal Pulmonary Hemorrhage following Concurrent Chemoradiotherapy in Stage 3B/C Squamous-Cell Lung Carcinoma Patients. J Oncol. 2018 Nov 1;2018:4518935. doi: 10.1155/2018/4518935. eCollection 2018.
  • Onal C, Akkus Yildirim B, Yuce Sari S, Yavas G, Gultekin M, Guler OC, Yildiz F, Akyurek S.: Treatment outcomes of endometrial cancer patients with paraaortic lymph node metastasis: A multi-institutional analysis. 2018 Int J Gynecol Cancer
  • Gultekin M, Beduk Esen CS, Balci B, Alanyali S, Akkus Yildirim B, Guler OC, Yuce Sari S, Ergen SA, Sahinler I, Alsan Cetin I, Onal C, Yildiz F, Ozsaran Z. Role of vaginal brachytherapy boost following adjuvant external beam radiotherapy in cervical cancer: Turkish Society for Radiation Oncology Gynecologic Group Study (TROD 04-002). Int J Gynecol Cancer . 2021 Feb;31(2):185-193.
  • Onal C, Ozyigit G, Akgun Z, Atalar B, İgdem S, Oymak E, Agaoglu F, Selek U, Guler OC, Hurmuz P, Mustafayev TZ, Akyol F.: Oligometastatic bone disease in castration-sensitive prostate cancer patients treated with stereotactic body radiotherapy using 68Ga-PSMA-PET/CT: TROD 09-004 study. Clin Nucl Med. 2021 Jun 1;46(6):465-470. doi: 10.1097/RLU.0000000000003558.
  • Onal C, Sari SY , Yildirim BA, Yavas G, Gultekin M , Guler OC, Akyurek S, Yildiz F: A multi-institutional analysis of sequential versus ‘sandwich’ adjuvant chemotherapy and radiotherapy for stage IIIC endometrial carcinoma. J Gynecol Oncol. 2018 Mar;30(2):e28
  • Yildirim BA, Onal C, Kose F, Oymak E, Sedef AM, Besen AA, Aksoy S, Guler OC, Sumbul AT, Muallaoglu S, Mertsoylu H, Ozyigit G. Outcome of loco-regional radiotherapy in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate. Strahlenther Onkol. 2019 Jan 30. doi: 10.1007/s00066-019-01429-6. [Epub ahead of print]
  • Onal C, Yuce Sari S, Yavas G, Oymak E, Duru Birgi S, Yigit E, Guler OC, Gultekin M, Akyurek S, Yildiz F.: Outcome and safety analysis of endometrial cancer patients treated with postoperative 3D-conformal radiotherapy or intensity modulated radiotherapy. Acta Oncol. 2021 Sep;60(9):1154-1160. doi: 10.1080/0284186X.2021.1926537. Epub 2021 May 17.
  • Ozyigit G, Onal C, Igdem S, Arican Alicikus Z, Iribas A, Akin M, Yalman D, Cetin I, Aksu MG, Atalar B, Dincbas F, Hurmuz P, Guler OC, Aydin B, Sert F, Yildirim C1, Gorken IB, Agaoglu FY, Korcum AF, Yuce D, Ozkok S, Darendeliler E, Akyol F.: Treatment outcomes of prostate cancer patients with Gleason score 8 - 10 treated with definitive radiotherapy: TROD 09-001 multi-institutional study. Strahlenther Onkol. 2019. October
  • Onal C, Sedef AM, Kose F, Oymak E, Guler OC, Sumbul AT, Aksoy S, Yıldırım BA, Besen AA, Muallaoglu S, Mertsoylu H, Ozyigit G. The hematologic parameters in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate. Future Oncology. 2019
  • Onal C, Yuce Sari S, Yildirim BA, Gultekin M, Guler OC, Yildiz F. Is There Any Benefit of Paraaortic Field Irradiation in Pelvic Lymph Node Positive Endometrial Cancer Patients? A Propensity Match Analysis. J Obstet Gynaecol, 1-8 2019 Dec 3[Online ahead of print]
  • Topkan E, Ozdemir Y, Kucuk A, Guler OC, Sezer A, Besen AA, Mertsoylu H, Senyurek S, Kilic Durankus N, Bolukbasi Y, Selek U, Pehlivan B. Low Advanced Lung Cancer Inflammation Index Predicts Poor Prognosis in Locally Advanced Nasopharyngeal Carcinoma Patients Treated with Definitive Concurrent Chemoradiotherapy. J Oncol . 2020 Oct 7;2020:3127275.
  • Onal C, Gultekin M, Oymak E, Guler OC, Yilmaz MT, Sari SY, Yildirim BA, Yildiz F. Stereotactic Radiotherapy in Patients With Oligometastatic or Oligoprogressive Gynecological Malignancies: A Multi-Institutional Analysis. Int J Gynecol Cancer. 2020 Jun;30(6):865-872.
  • Onal C, Kose F, Ozyigit G, Aksoy S, Oymak E, Muallaoglu S, Guler OC, Tilki B, Hurmuz P, Akyol F.: Stereotactic body radiotherapy for oligoprogressive lesions in metastatic castration-resistant prostate cancer patients during abiraterone/enzalutamide treatment. Prostate. 2021 Jun;81(9):543-552. doi: 10.1002/pros.24132
  • Hurmuz P, Onal C, Ozyigit G, İgdem S, Atalar B, Sayan H, Akgun Z, Kurt M, Basak Ozkok H, Selek U, Oymak E, Tilki B, Guler OC, Mustafayev TZ, Saricanbaz İ, Rzazade R, Fadil Akyol.: Treatment outcomes of metastasis-directed treatment utilising 68Ga-PSMA-PET/CT for oligometastatic or oligorecurrent prostate cancer: Turkish Society for Radiation Oncology Group Study (TROG 09-002). Strahlenther Onkol. 2019 Oct;195(10):882-893. doi: 10.1007/s00066-019-01476-z. Epub 2019 May 29.
  • Onal C, Torun N, Oymak E, Guler OC, Reyhan M, Yapar AF. Retrospective Correlation of 68 Ga-Psma Uptake With Clinical Parameters in Prostate Cancer Patients Undergoing Definitive Radiotherapy. Ann Nucl Med. 2020 Jun;34(6):388-396
  • Onal C, Bozca R, Oymak E, Guler OC. Comparison of helical and TomoDirect techniques with simultaneous integrated boost in early breast cancer patients. Rep Pract Oncol Radiother. 2023 Aug 28;28(4):541-550. doi: 10.5603/RPOR.a2023.0058.
  • Yavas G, Guler OC, Gultekin M, Oymak E, Yuce Sari S, Yildiz F, Onal C.Multi-institutional study on the role of postoperative radiotherapy in elder endometrial cancer patients - Int J Gynecol Cancer. 2023 Jan 12;ijgc-2022-004034.
  • Oymak E, Bozca R, Guler OC, Onal C. Contralateral breast radiation doses in breast cancer patients treated with helical tomotherapy. Medical Dosimetry 2022 december
  • Onal C, Erbay G, Oymak E, Guler OC. The impact of the apparent diffusion coefficient for the early prediction of the treatment response after definitive radiotherapy in prostate cancer patients. Radiother Oncol. 2023 Jul:184:109677. doi: 10.1016/j.radonc.2023.109677. Epub 2023 Apr 20.
  • Onal C, Bozca R, Dolek Y, Guler OC, Arslan G. Incidental Testicular Doses During Volumetric-Modulated Arc Radiotherapy in Prostate Cancer Patients. Radiol Med. 2020 Mar 3.
  • Onal C, Erbay G, Guler OC, Yavas C, Oymak E. Treatment outcomes of simultaneous integrated boost to intraprostatic lesions with external beam radiotherapy in localized prostate cancer patients. Prostate. 2023 Sep;83(12):1158-1166. doi: 10.1002/pros.24558. Epub 2023 May 12.
  • Yuce Sari S, Guler OC, Oymak E, Gultekin M,Yigit E,Kahvecioglu A,Yuce K, Celik H, Usubutun A, Bolat F, Onal C, Yildiz F. Uterine papillary serous and clear cell carcinomas: Comparison of Characteristics and Clinical Outcomes. The Journal of Obstetrics and Gynaecology Research.
  • Kandaz M, Guler OC, Memiş Y, Bahat Z, Canyılmaz E, Yoney A.: Evaluation of prognostic factors and survival results in pediatric hodgkin ‘s lymphoma – single center experience from eastern black sea region of turkey. J Hematol Blood Disord 2017: 3 (1):101
  • Kandaz M, Çekiç AB, Güler OC, Usta MA, Güner A, Türkyılmaz S, Yöney A. Long-term Effect of Chemoradiotherapy at Gastric Cancer on Pancreas. IOSR-JDMS. 2017:16(11):45-51.
  • Alemdaroglu S, Durdag GD, Baran SY, Simsek SY, Yetkinel S, Yaginc DA, Guler OC, Celik H. Prognostic factors of endometrial cancer in elderly patient group and their effects on survival. North Clin Istanb. 2021 Jan 14;8(4):345-353.
  • Onal C, Akkus Yildirim B, Guler OC.: Outcomes of aggressive treatment in esophageal cancer patients with synchronous solitary brain metastasis. Molecular and Clinical Oncology 7: 107-112, 2017.
  • Onal C, Demiral AN, Atalar B, Yalman D, Dagoglu N, Hurmuz P, Erpolat P, Akyurek S, Karabulut Gul S, Berber T, Guler OC, Umay C, Sert F, Karahacioglu E, Birgi SD, Yaprak G, Kaytan Saglam E. National, Observational, Multicentric Retrospective Study to Understand Treatment Patterns, Patient Journey and Characteristics with Stage III Non-Small Cell Lung Cancer Patients in Turkey: Stone Trial. International Journal of Hematology and Oncology Number: 1 Volume: 32 Year: 2022 23 doi: 10.4999/uhod.225876
  • Onal C, Gultekin M, Yavas G, Oymak E, Yuce Sari S, Guler OC, Yigit E, Yildiz F. The impact of serum albumin-to-alkaline phosphatase ratio in cervical cancer patients treated with definitive chemoradiotherapy. J Obstet Gynaecol. 2022 Jun 2;1-7. doi: 10.1080/01443615.2022.2069484.
  • Guler OC, Bal N, Onal C.: Metachronous Prostate Metastasis of Renal Cell Carcinoma: Case Report and Review of the Literature. Clin Genitourin Cancer. 2016 Apr;14(2):e211-3
  • Guler OC, Onal C, Arslan G.: Graves' ophthalmopathy treated with protracted hypofractionated low-dose adaptive radiotherapy: case report and review of the literature. Wien Klin Wochenschr. 2015 Oct 14.
  • Guler OC, Onal C, Erbay G, Bal N.: Prostate mucinous carcinoma treated with definitive radiotherapy and hormonotherapy: Case report and review of the literature. Clin Genitourin Cancer. 2013 Nov 12. pii: S1558-7673(13)00289-9. doi: 10.1016/j.clgc.2013.11.018.
  • Guler OC, Onal C, Ozyar E: Concurrent Cisplatin and Radiotherapy Versus Cetuximab and Radiotherapy, an Unsolved Problem. Annals of Oncology 2017 December [Article in press].
  • Guler OC, Onal C. : Regional Nodal Irradiation for Clinically Node-Positive Breast Cancer Patients with Pathologic Negative Nodes after Neoadjuvant Chemotherapy. In regard to Schlafstein et al. Clinical Breast Cancer. DOI:https://doi.org/10.1016/j.clbc.2021.09.010
  • Guler OC, Onal C.: Validating Modern NRG Oncology Pelvic Nodal and Groupe Francophone de Radiothérapie Urologique Prostate Bed Contouring Guidelines for Post-prostatectomy Salvage Radiation: A Secondary Analysis of the LOCATE Trial. In regard to Harmon et al. Int J Radiat Oncol Biol Phys. 2021
  • Guler OC, Onal C.: Pattern of Recurrence After Stereotactic Radiotherapy in Prostate Cancer Patients With Nodal Pelvic Relapse. A Multi-Institutional Retrospective Analysis. In regard to Francolini et al. Clinical Oncology. 2021
  • Guler OC, Onal C. Oncological outcomes of squamous cell carcinoma of the cervical esophagus treated with definitive (chemo?)radiotherapy: a systematic review and meta?analysis. In regard to De Virgilio et al. J Cancer Res Clin Oncol. 2022 Jun 13. doi: 10.1007/s00432-022-04118-7.
  • Guler OC, Onal C. Stereotactic Radiotherapy for Lesions Detected via 68 Ga-Prostate-specific Membrane Antigen and 18 F-Fluorodexyglucose Positron Emission Tomography/Computed Tomography in Patients with Nonmetastatic Prostate Cancer with Early Prostate-specific Antigen Progression on Androgen Deprivation Therapy: A Prospective Single-center Study. In regard to Pan et al. Eur Urol Oncol. 2022 May 13:S2588-9311(22)00063-3.
  • Guler OC, Onal C. Re: Androgen deprivation therapy and radiotherapy in intermediate risk prostate cancer: A randomized phase III trial. Eur J Cancer. 2022 Mar 10;S0959-8049(22)00078-8.
  • Guler OC, Isci O, Onal C. Re: Rhonda L. Bitting, Patrick Healy, Daniel J. George, et al. Phase II Trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in Men with High-risk Prostate-specific Antigen Recurrent Prostate Cancer: The STREAM Trial. Eur Urol Oncol 2021;4:948-54 Eur Urol Oncol. 2022 Mar 17:S2588-9311(22)00033-5.
  • Onal C, Guler OC. Longer treatment time and lower radiation doses-an alternative for Graves' ophthalmopathy treatment. Strahlenther Onkol. 2021 Oct 1. doi: 10.1007/s00066-021-01852-8.
  • Onal C, Guler OC, Oymak E. Patterns of Recurrence and Modes of Progression After Metastasis-Directed Therapy in Oligometastatic Castration-Sensitive Prostate Cancer. In Regard to Deek et al. Int J Radiat Oncol Biol Phys. 2021 Aug 1;110(5):1546-1547
  • Topkan E, Guler OC, Bal N, Ozdemir Y: Adjuvant radiotherapy in management of trichilemmal carcinoma of left nasal alae with positive surgical margins: A case report Case Reports in Clinical Pathology. 2016 Doi: 10.5430/crcp.v3n4p57
  • Onal C, Oymak E, Guler OC. Long-term Outcomes of Cervical Cancer Patients Treated With Definitive Chemoradiation Following a Complete Metabolic Response.: in regard to Lin et al. Clin Oncol (R Coll Radiol). 2021 Aug;33(8):e360
  • Onal C, Oymak E, Guler OC. Upfront metastasis?directed therapy in oligorecurrent prostate cancer does not decrease the time from initiation of androgen deprivation therapy to castration resistance: in regard to Triggiani et al. Med Oncol. 2021 Jun 11;38(7):81.
  • Onal C, Oymak E, Guler OC. NRG oncology updated international consensus atlas on pelvic lymph node volumes for intact and postoperative prostate cancer: In Regard to Hall et al. Int J Radiat Oncol Biol Phys . 2021 Jun 1;110(2):619-620.
  • Oymak E, Yildirim BA, Guler OC, Onal C: Responding to Veiga et al. 'Long term radiological features of radiation-induced lung damage'. Radiother Oncol. 2018 Jul 16. pii: S0167-8140(18)33345-0.
  • Kandaz M, Karaman E, Guler OC, Mungan S, Yoney A. : Endometrial Adenosarkoma: Case Report. Annals of Clinical Case Reports – Oncology: 2016,1;1170.
  • Onal C, Oymak E, Guler OC: Re: Metastasis-directed Therapy in Prostate Cancer: Prognostic Significance of the ESTRO/EORTC Classification in Oligometastatic Bone Disease. Clin Oncol (R Coll Radiol). 2021 Dec 30;S0936-6555(21)00499-4.
  • Onal C, Elmali A, Guler OC: Outcomes of Cytoreductive Radical Prostatectomy for Oligometastatic Prostate Cancer on Prostate-specific Membrane Antigen Positron Emission Tomography: Results of a Multicenter European Study. In regard to Rajwa et al. Eur Urol Oncol (2023)
  • Onal C, Oymak E, Guler OC. There is no doubt about the winner of the lion-rabbit fight. Prostate. 2022 Jun 2. doi: 10.1002/pros.24377
  • Güler OC, Kandaz M, Bahat Z, Canyılmaz E, Çakır E, Yoney A: Prognostic Value of Pretreatment HER2 Status in Gastric Cancer Patients Treated with Postoperative Chemoradiotherapy. Turkish Journal of Oncology. 2017, Vol 32, Num 3.
  • Guler OC, Torun N, Yıldırım BA, Onal C: Prognostic Value of Metabolic Response Measured by FDG-PET-CT in Patients with Breast Cancer Liver Metastasis Treated with Stereotactic Body Radiotherapy. Turkish Journal of Oncology. 2018, Vol 33, Num 3.
  • Güler OC, Önal C.: Lokalize Prostat Kanserinde Radyoterapi. Turkiye Klinikleri J Urology-Special Topics 2017;10(2):150-6
  • Güler OC, Canyılmaz E: Larinks Kanserinde Radyoterapi. Türkiye Klinikleri Journal of Ear Nose and Throat-Special Topics 2017;10(3):192-8
  • Güler OC, Özdemir Y, Önal C.: Metastatik Evre ve Lokal Nükslerde Radyoterapi. Turkiye Klinikleri J Radiat Oncol-Special Topics 2015;1(2):45-53.
  • Güler OC, Önal C.: Hepatoselüer Karsinomda Radyoterapi. Turkiye Klinikleri J Gastroenterohepatol - Special Topics 2014; 7(2):67-74.
  • Guler OC, Onal C: Mide Kanserinde Definitif Radyoterapi. Üst Gastrointestinal Kanserlerde Radyoterapi. 1. Baskı. Ankara: Türkiye Klinikleri; 2018. p.29-33.
  • Güler OC, Önal C.: Kasa İnvaze Mesane Kanserlerinde Adjuvan ve Neoadjuvan Radyoterapi. Ürolojik Onkoloji Bülteni, Ürotelyal Kanseri 2020; Cilt 4 - Sayı 1: 45-49.
  • Güler OC, Önal C.: Prostat Kanseri Radyoterapisinde PSMA-PET Güvenilirliği ve Kısıtlılığı. Nucl Med Semin 2023; 9: 171-177
  • Oymak E, Guler OC, Onal C. Dosimetric Comparison of Volumetric Arc Therapy Methods for Stereotactic Body Radiotherapy in Liver Metastasis. Turk J Oncol 2022;37(4):453–61 doi: 10.5505/tjo.2022.3702
  • Oymak SE, Güler OC, Önal C.: Hepatobiliyer Sistem Tümörlerinde MR Kılavuzluğunda Adaptif Radyoterapi. Radyoterapide Yeni Bir Teknoloji: MR - Linak’ın Güncel Kullanımı – 2022. Türkiye Klinikleri; 2022. p.62-6.
  • Kandaz M, Guler OC, Yazar U, Ucuncu SY, Yoney A: Impact of Peritumoral Edema on Overall Survival in Glioblastoma Multiforme. Turkish Journal of Oncology. 2016;31 (3):83-88
  • Kandaz M, Guler OC, Karaman E, Mungan S, Yoney A: Malignant Mesenchymal Tumor of the Prostate: A Case Report. Turkish Journal of Oncology. 2017;32(4):169–72
  • Yıldırım BA, Su?mbu?l AT, Topkan E, O?zdemir Y, Bes?en AA, Gu?ler OC, Sedef AM, Onal C: Adjuvant uzatılmıs? temozolamid tedavisinin glioblastoma multiforme hastalarının sag?kalımına etkisi. Cukurova Med J 2018;43(3): DOI: 10.17826/cumj.335536
  • Yıldırım BA, Su?mbu?l AT, Gu?ler OC, Sedef AM, Önal C, Topkan E: Preoperatif kemoradyoterapi uygulanan lokal ileri rektum kanserli hastalarda tedavi öncesi hemoglobin du?zeyinin prognoszdaki rolu?. Cukurova Med J 2018;43(3) DOI: 10.17826/cumj.335761
  • KİTAP EDİTÖRLÜĞÜ VE BÖLÜM YAZARLIĞI
  • Guler OC, Onal C.: Bladder Preservation Therapies in Bladder Cancer. Principles and Practice of Urooncology: Radiotherapy, Surgery and Systemic Therapy. Editors: Ozyigit Gokhan, Selek Ugur (Eds.) Doi:10.1007/978-3-319-56114-1_3
  • Guler OC, Onal C.: Advanced Radiotherapy Techniques in Prostate Cancer. Principles and Practice of Urooncology: Radiotherapy, Surgery and Systemic Therapy. Editors: Ozyigit Gokhan, Selek Ugur (Eds.) Doi:10.1007/978-3-319-56114-1_3
  • Topkan E, Guler OC, Selek U: Radiochemotherapy and Fractionation in Locally Advanced Non-small-cell Lung Cancer: Principles and Practice of Radiotherapy Techniques in Thoracic Malignancies. ISBN 978-3-319-28761-4
  • Onal C, Guler OC.: The Role and Prognostic Value of PET-CT in Patients with Cervical Cancer Treated with Definitive Radiotherapy. Cervical Cancer: Recent Research and Review Studies. SM Group 2016. ISBN: 978-1-944685-91-1.
  • Ozyigit G, Hurmuz P, Yuce Sari S, Onal C, Biltekin F, Gultekin M, Yazici G, Guler OC, Akyol F.: Radiation Oncology A Case-Based Review. Editors: Ozyigit, Gokhan, Selek, Ugur (Eds.). ISBN 978-3-319-97145-2.
  • Meme Kanseri: Editörler: Özgür Özyılkan, Ali Murat Sedef, Hüseyin Özgür Aytaç, Ozan Cem Güler. Akademisyen Kitabevi. 2019
  • Sarkomlar ve Cilt Tümörleri: Editörler: Ali Murat Sedef, Ozan Cem Guler. Akademisyen Kitabevi. 2019
  • Gastrointestinal Sistem Tümörleri-1: Editörler: Hüseyin Mertsoylu, Ali Murat Sedef, hüsyin Özgür Aytaç, Ozan Cem Güler. Akademisyen Kitabevi. 2019
  • Gastrointestinal Sistem Tümörleri-2: Editörler: Hüseyin Mertsoylu, Ali Murat Sedef, hüsyin Özgür Aytaç, Ozan Cem Güler. Akademisyen Kitabevi. 2019
  • Genitoüriner Sistem Tümörleri: Editörler: Fatih Köse, Ayberk Beşen, Ali Murat Sedef, Ozan Cem Guler. Akademisyen Kitabevi. 2019
  • Jinekolojik Tümörler: Editörler: Fatih Köse, Ayberk Beşen, Ali Murat Sedef, Ozan Cem Guler. Akademisyen Kitabevi. 2019
  • Onkolojide Palyatif Bakım ve Yaşam Sonu Desteği: Editörler: Ali Murat Sedef, Ozan Cem Güler. Akademisyen Kitabevi. 2019
  • Klinik Radyasyon Onkolojisi El Kitabı: Editörler: Cem Önal, Erkan Topktan, Esra Kaytan Sağlam, Ferah Yıldız, Gökhan Özyiğit, Nilgün Özbek Okumuş, Ozan Cem Güler, Petek Erpolat, Serap Akyürek, Uğur Selek, Zeynep Özsaran. ISBN 978-625-74968-7-2.
  • ULUSLARARASI BİLDİRİLER
  • Topkan E, Parlak C, Guler OC, Pehlivan B, Selek U. Impact Of Pretreatment Leukocytosis On Prognosis In Locally Advanced Non-Small Cell Lung Cancer Patients Treated With Concurrent Chemoradiotherapy. 15th World Conference on Lung Cancer, Sydney, Australia. J Thorac Oncol 8 (Supplement 2): s412: 2013.
  • Topkan E, Yildirim BA, Guler OC, Parlak C. Impact of Presence and Degree Of Pretreatment Weight Loss In Locally Advanced Pancreatic Carcinoma Patients Treated With Definitive Concurrent Chemoradiotherapy. 3rd. International Gastrointestinal Cancer Conference, Antalya, Turkey. Abstract Book Page 15; 2013.
  • Topkan E, Yildirim BA, Guler OC, Ozdemir Y. Survival Analysis of 51 Leptomeningeal Metastatic Non Small Cell Lung Cancer Patients Treated with Whole Brain Radiotherapy 16th World Conference on Lung Cancer (WCLC 2015). 6-9 sep 2015
  • Topkan E, Yildirim BA, Guler OC, Ozdemir Y. Elective Nodal Irradiation Does Not Alter Isolated Nodal Failure and Survival Outcomes in Stage III NSCLC Patients Undergoing Chemoradiotherapy 16th World Conference on Lung Cancer (WCLC 2015). 6-9 sep 2015
  • Topkan E, Yildirim BA, Guler OC, Ozdemir Y. Prognosis of Stage III NSCLC Patients Presenting with Isolated BrainFailure after Definitive Concurrent Chemoradiotherapy 16th World Conference on Lung Cancer (WCLC 2015). 6-9 sep 2015
  • Onal C, Guler OC, Yildirim BA.: Prognostic utility of pretreatment hematologic parameters in patients receiving definitive chemoradiation therapy for cervical cancer. American Society for Radiation Oncology 57th Annual Meeting, 25 - 28 September 2016, Boston, USA.
  • Yildirim BA, Guler OC, Onal C The correlation between FDG-PET parameters and hematologic parameters in patients with esophageal squamous-cell carcinoma treated with definitive chemotherapy ECCO2017
  • Kandaz M, Bahat Z, Güler OC, Canyilmaz E, Melikoğlu M, Yöney A. Radiotherapy in The Management of Classic Kaposi's Sarcoma: A Single Institution Experience from North East Turkey. Intercos Winter Meeting 2017. 16- 19 November 2017, Havana, Cuba.
  • Guler OC, Besen AA: The impact of Ga68 PSMA PET for evaluatig the treatment response in prostate cancer patients receiving neoadjuvant hormonotherapy. 8th Euroasian Uro-Oncology Congress. 28 June-1 July 2018, Tbilisi, Georgia.
  • Onal C, Torun N, Hurmuz P, Guler OC, Tuncel M, Akkus Yildirim B, Caglar M, Reyhan M, and others.: Integration of 68Ga-PSMA-PET/BT in Radiation Therapy Planning for Prostate Cancer Patients: A Multi-Institutional Analysis. American Society for Radiation Oncology (ASTRO) 60th Annual Meeting, October 21 - 24, 2017, San Antonio, USA.
  • Parlak C, Guler OC, Selek U, Ozyilkan O, Topkan E. Does FDG-PET-CT Based Re-Staging Influences Initial Management Decision And Clinical Outcome In Patients With Locally Advanced Pancreatic Carcinoma Planned To Undergo Chemoradiotherapy? 37th ESMO Annual Meeting, Vienna, Austira. Ann Oncol 23 (Supplement 9): ix237: 2012
  • Parlak C, Guler OC, Ozyilkan O,Topkan E. Timing And Patterns Of Disease Progression Following Concurrent Radiochemotherapy In Patients With Unresectable Locally-Advanced Pancreas Cancer. 37th ESMO Annual Meeting, Vienna, Austira. Ann Oncol 23 (Supplement 9): ix238: 2012.
  • Parlak C, Guler OC, Ozyilkan O. Definitive Thoracic Chemoradiotherapy in Non-Small Cell Lung Cancer Patients with Solitary Brain Metastasis. 37th ESMO Annual Meeting, Vienna, Austira. Ann Oncol 23 (Supplement 9): ix425: 2012.
  • Yuksel O, Parlak C, Guler OC, Onal C, Ozyilkan O, Topkan E.: Effect of zoledronic acid used concurrently with radiation therapy on growth of bone epiphysesal plaque. 37th ESMO Congress Vienna, Austria, 28 September – 2 October 2012.
  • Parlak C, Guler OC, Ozyilkan O, Topkan E. Impact Surgical Resection And Radiosurgery Directed To Brain Metastasis On Survival Outcomes In Non-Small Cell Lung Cancer Patients With Synchronous Single Brain Metastasis. 15th World Conference on Lung Cancer, Sydney, Australia. J Thorac Oncol 8 (Supplement 2): s836: 2013.
  • Topkan E, Parlak C, Guler OC, Selek U, Ozyilkan O. Prognostic Value Of Number Of Chemotherapy Cycle In Stage IIIB Non-Small Cell Lung Cancer Patients Treated With Thoracic Radiotherapy And Concurrent Cisplatin-Vinorelbine. 15th World Conference on Lung Cancer, Sydney, Australia. J Thorac Oncol 8 (Supplement 2): s550: 2013.
  • Topkan E, Parlak C, Guler OC, Selek U. Prognostic Value Of Age In Patients Receiving Concurrent Chemoradiotherapy With Diagnosis Of Stage IIIB Non-Small Cell Lung Cancer. 15th World Conference on Lung Cancer, Sydney, Australia. J Thorac Oncol 8 (Supplement 2): s555: 2013.
  • Topkan E, Parlak C, Guler OC, Pehlivan B, Ozyilkan O, Selek U. Impact Of Change In Hemoglobin Levels During Treatment On Prognosis In Non-anemic Locally Advanced Non-Small Cell Lung Cancer Patients Treated With Concurrent Chemoradiotherapy. 15th World Conference on Lung Cancer, Sydney, Australia. J Thorac Oncol 8 (Supplement 2): s853: 2013.
  • Topkan E, Parlak C, Guler OC, Selek U. Survival Outcome In Stage IIIB Non-Small Cell Lung Cancer Patients Younger Than 45 Years: Retrospective Analysis Of 145 Patients. 15th World Conference on Lung Cancer, Sydney, Australia. J Thorac Oncol 8 (Supplement 2): s1149: 2013.
  • Erbay G, Onal C, Guler OC, Karadeli E, Koc Z.: Predicting the tumor response with Diffusion-weighted imaging in cervical cancer patients treated with definitive chemoradiotherapy. 20th European Symposium on Urogenital Radiology. Istanbul, Turkey. 19 – 22 September 2013.
  • Erbay G, Onal C, Guler OC, Koc Z.: The correlation of pharmacokinetic parameters of dynamic contrast-enhanced MR imaging in tumors and normal prostate gland. 20th European Symposium on Urogenital Radiology. Istanbul, Turkey. 19 – 22 September 2013.
  • Erbay G, Onal C, Guler OC, Karadeli E, Koc Z.: The predictive value of apparent diffusion coefficient changes in prostate cancer patients treated with radiotherapy. 20th European Symposium on Urogenital Radiology. Istanbul, Turkey. 19 – 22 September 2013.
  • Erbay G, Onal C, Reyhan M, Guler OC, Koc Z.: Prognostic values of pretreatment SUVmax and ADCmean in cervical cancer patients treated with definitive chemoradiotherapy. 20th European Symposium on Urogenital Radiology. Istanbul, Turkey. 19 – 22 September 2013.
  • Erbay G, Onal C, Reyhan M, Guler OC, Koc Z.: ADCmean is a predictive marker for metabolic response in cervical cancer patients treated with chemoradiotherapy. 20th European Symposium on Urogenital Radiology. Istanbul, Turkey. 19 – 22 September 2013.
  • Oymak E, Onal C, Guler OC, Findikcioglu A, Reyhan M.: Isolated false positivity of mediastinal lymph nodes on FDG/PET-CT in patients with endometrial cancer: Case report. 18th International Meeting of the European Society of Gynaecological Oncology (ESGO), Liverpool, UK. 19 - 22 October 2013.
  • Onal C, Reyhan M, Parlak C, Guler OC, Oymak E.: Prognostic value of pretreatment FDG uptake in cervical cancer patients treated with definitive chemoradiotherapy. 18th International Meeting of the European Society of Gynaecological Oncology (ESGO), Liverpool, UK. 19 - 22 October 2013.
  • Oymak E, Onal C, Efe E, Guler OC, Sonmez A.: Local control in patients with cervical cancer treated with 3d conformal brachytherapy. 18th International Meeting of the European Society of Gynaecological Oncology (ESGO), Liverpool, UK. 19 - 22 October 2013.
  • Oymak E, Onal C, Sonmez S, Guler OC, Arslan G.: Toxicity results in patients with cervical cancer treated with 3D conformal brachytherapy. 18th International Meeting of the European Society of Gynaecological Oncology (ESGO), Liverpool, UK. 19 - 22 October 2013.
  • Topkan E, Guler OC, Parlak C. Baseline Neutrophil to Lymphocyte Ratio Lower Than 4.6 is Associated with Superior Survival Outcomes in Newly Diagnozed Glioblastoma Multiforme Patients Treated with Concurrent Temozolomide and High dose Radiotherapy. VI.th Evidence Based Multidisciplinary Neurooncology Symposium, Istanbul, Turkey. Scientific Program and Abstract Book, Page77-78, 2013 (Poster)
  • Topkan E, Yildirim BA, Guler OC, Parlak C. Impact of Presence and Degree Of Pretreatment Weight Loss In Locally Advanced Pancreatic Carcinoma Patients Treated With Definitive Concurrent Chemoradiotherapy. 3rd. International Gastrointestinal Cancer Conference, Antalya, Turkey. Abstract Book Page 15; 2013 (Sozel).
  • Guler OC, Onal C, Arslan G, Sonmez S.: Comparison of IMRT and VMAT plans with different energy levels using Monte Carlo algorithm for prostate cancer. ESTRO 33 April 04-08, 2014 Vienna, Austria.
  • Guler OC, Onal C, Dolek Y, Erbay G.: Uterine perforation during three-dimensional image-guided brachytherapy in cervical cancer patients. ESTRO 33 April 04-08, 2014 Vienna, Austria.
  • Onal C, Guler OC, Sonmez S, Erbay G, Arslan G.: Simultaneous integrated boost to intraprostatic lesions using different energy levels of IMRT and VMAT. ESTRO 33 April 04-08, 2014 Vienna, Austria.
  • Onal HC, Guler OC, Reyhan M, Yapar AF.: Treatment outcomes of patients with cervical cancer with complete metabolic responses after definitive CHRT. ESTRO 33 April 04-08, 2014 Vienna, Austria.
  • Guler OC, Bal N, Onal C.: Prostat metastazı yapan renal hücreli karsinom: Olgu sunumu. 6th Uro-oncology Winter Congress and Course, 29.01 – 01.02.2015 Baku, Adzerbaijan.
  • Yıldırım BA, Guler OC, Bal N, Onal C.: Sistemik tedavi ve radyoterapi ile tedavi edilen prostat sarkomatoid karsinomu: Olgu Sunumu. 6th Uro-oncology Winter Congress and Course, 29.01 – 01.02.2015 Baku, Adzerbaijan.
  • Guler OC, Sari SY, Birge SD, Gultekin M, Yildiz F, Onal C.: Treatment outcomes of definitive or postoperative radiotherapy in elderly cervical cancer patients. 18th ECCO – 40th ESMO, European Cancer Congress, 25 - 29 September 2015, Vienna, Austria.
  • Onal C, Guler OC, Yildirim BA, Torun N.: The impact of SUVmax for evaluation of treatment response in esophageal carcinoma patients treated with definitive chemoradiotherapy. 18th ECCO – 40th ESMO, European Cancer Congress, 25 - 29 September 2015, Vienna, Austria.
  • Onal C, Guler OC, Yildirim BA, Torun N.: The importance of positron emission tomography parameters in esophageal carcinoma treated with radiotherapy. 18th ECCO – 40th ESMO, European Cancer Congress, 25 - 29 September 2015, Vienna, Austria.
  • Topkan E, Yıldırım BA, Guler OC, Ozdemir Y. Factors Associated with Brain Metastasis Development in Radically Treated Stage IIIB Non-Small Cell Lung Cancer Patients 16th World Conference on Lung Cancer (WCLC 2015) 6-9.sep 2015
  • Topkan E, Yıldırım BA, Ozdemir Y, Guler OC, Kose F. Effective Resolution of Lung Cancer Related Tracheal and/or Bronchial Obstruction with External Beam Radiotherapy 16th World Conference on Lung Cancer (WCLC 2015) 6-9.sep 2015
  • Topkan E, Yıldırım BA, Ozdemir Y, Guler OC, Ozyilkan O. Weight Loss before Radical Chemoradiotherapy Is Associated with Poorer Survival Outcomes in Overweight Locally Advanced NSCLC Patients 16th World Conference on Lung Cancer (WCLC 2015) 6-9.sep 2015
  • Onal C, Guler OC, Dolek Y, Cengiz M.: The role of delineation courses for improving observer variability in target delineation for gastric cancer. American Society for Radiation Oncology 57th Annual Meeting, 18 - 21 October 2015, San Antonio, USA.
  • Onal C, Guler OC, Torun N.: The importance of pretreatment PET-CT parameters in patients with esophageal carcinoma treated with radiation therapy. American Society for Radiation Oncology 57th Annual Meeting, 18 - 21 October 2015, San Antonio, USA.
  • Guler OC, Onal C, Erbay G, Torun N.: The prognostic significance of SUVmax on PET-BT and ADCmean on Diffusion-Weighted MRI in patients treated with definitive chemoradiation therapy. American Society for Radiation Oncology 57th Annual Meeting, 18 - 21 October 2015, San Antonio, USA.
  • Onal C, Erbay G, Guler OC.: Treatment response evaluation with ADCmean in cervical cancer patient treated with chemoradiotherapy. ESTRO 35, 29 April-03 May, 2016, Turin, Italy.
  • Yuce Sari S, Guler OC, Gultekin M, Onal C, Yildiz F.: Adjuvant small pelvic radiation therapy in cervical cancer patients with minor risk factors. American Society for Radiation Oncology 57th Annual Meeting, 25 - 28 September 2016, Boston, USA.
  • Onal C, Erbay G, Guler OC, Yildirim BA, Arslan G, Sonmez S.: The Feasibility and Toxicity Analysis of Simultaneous Integrated Boost of 86 Gy to Intraprostatic Tumor Delivered in 39 Fractions. American Society for Radiation Oncology 57th Annual Meeting, 25 - 28 September 2016, Boston, USA.
  • Yildirim BA, Onal C, Torun N, Ozdemir Y, Guler OC.: The correlation between FDG-PET parameters and hematologic parameters in patients with esophageal squamous-cell carcinoma treated with definitive chemoradiotherapy. ECCO2017 - European Cancer Congress - 27 – 30 January 2017, Amsterdam, The Netherlands.
  • Yildirim BA, Guler OC, Onal C.: The importance of prognostic nutritional index in cervical cancer patients treated with concomitant chemoradiotherapy. ECCO2017 - European Cancer Congress - 27 – 30 January 2017, Amsterdam, The Netherlands.
  • Onal C, Guler OC, Yildirim BA, Torun N. The importance of positron emission tomography parameters in esophageal carcinoma treated with radiotherapy European Cancer Cancer (ECCO) Congress 27-30 January 2017 Amsterdam, The Netherland
  • Onal C, Guler OC, Yildirim BA, Torun N. The impact of SUVmax for evaluation of treatment response in esophageal carcinoma patients treated with definitive chemoradiotherapy European Cancer Cancer (ECCO) Congress 27-30 January 2017 Amsterdam, The Netherland
  • Engels B, Guler OC, Onal C, De Ridder M.: Prostate-specific membrane antigen (PSMA) PET-CT guided radiotherapy in oligometastatic prostate cancer. 2017 Genitourinary Cancers Symposium – 16 – 18 February 2017, Orlando, USA.
  • Onal C, Torun N, Hurmuz P, Guler OC, Tuncel M, Yıldırım BA, Caglar M, Reyhan M, Akyol F, Ozyigit F. Integration of 68ga-PSMA-PET/BT in Radiation Therapy Planning for Prostate Cancer Patients: A Multi-Institutional Analysis. American Society for Radiation Oncology Annual Meeting, 21 - 24 October 2018, San Antonio, USA.
  • Yıldırım BA, Onal C, Sarı SY, Yavas G, Gultekin M, Guler OC, Yıldız F, Akyurek S. The Utility of Dissected Lymph Node Number and Lymph Node Metastasis Ratio In Stage IIIC Endometrium Adenocarcinoma: A Multicentric Analysis. American Society for Radiation Oncology Annual Meeting, 21 - 24 October 2018, San Antonio, USA.
  • Onal C, Yuce Sari S, Akkus Yildirim B, Yavas G, Gultekin M, Guler OC, Akyurek S, Yildiz F.: A Multi-Institutional Analysis for Sequential Adjuvantchemotherapy and Radiation Versus "Sandwich" MultiÃá-ModaliÃáty for STAGE IIIC Endometrial Carciinoma. American Society for Radiation Oncology (ASTRO) 60th Annual Meeting, October 21 - 24, 2017, San Antonio, USA.
  • Akkus Yildirim B, Onal C, Yuce Sari S, Yavas G, Gultekin M, Guler OC, Yildiz F, Akyurek S.: The Utility of Dissected Lymph Node Number and Lymph Node Metastasis Ratio In Stage IIIC Endometrium Adenocarcinoma: A Multicentric Analysis. American Society for Radiation Oncology (ASTRO) 60th Annual Meeting, October 21 - 24, 2017, San Antonio, USA.
  • Onal C, Torun, Guler OC, Reyhan M, Akkus Yildrim B, Yapar AF.: Is there a correlation between Gleason score and maximum standardized uptake value in locally advanced prostate cancer patients?. ASCO 2019 Genitourinary Cancers Symposium, 14 - 16 February 2019, San Fransisco, USA.
  • Yildirim B, Onal C, Kose F, Oymak E, Sedef AM, Besen AA, Aksoy S, Guler OC, Sumbul AT, Mertsoylu H, Ozyigit G.: The outcome of loco-regional radiotherapy in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate. ASCO 2019 Genitourinary Cancers Symposium, 14 - 16 February 2019, San Fransisco, USA.
  • Onal C, Sedef AM, Kose F, Oymak E, Guler OC, Sumbul AT, Aksoy S, Akkus Yildrim B, Besen AA, Mullaoglu S, Mertsoylu H, Ozyigit G.: The hematologic parameters in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate. ASCO 2019 Genitourinary Cancers Symposium, 14 - 16 February 2019, San Fransisco, USA.
  • Onal C, Demiral A, Atalar B, Yalman D, Gul S, Hurmuz P, Erpolat P, Akyurek S, Berber T, Guler OC, Umay C, Sert F, Dagoglu N, Yaprak G, Karahacioglu E, Duru Birgi S, Kaytan Saƒülam E.: National, observational, multicentric study in stage III non-small cell lung cancer patients in Turkey: Stone trial. 2019 World Conference on Lung Cancer, September 7-10, 2019, Barcelona, Spain.
  • Onal C, Hurmuz P, Torun N, Tuncel M, Guler OC, Reyhan M, Caglar M, Ozyigit G.: The Role of 68Ga-PSMA-PET/CT in Pelvic field Delineation in Prostate Cancer Patients with Pelvic Lymph Node Metastasis. American Society for Radiation Oncology (ASTRO) 61th Annual Meeting, September 11 - 15, 2017, Chicago, USA.
  • Onal C, Efe E, Akkus Yildirim B, Guler OC.: Dosimetric Comparison of Simultaneous-Integrated boost and Sequential boost with VMAT or Helical Tomotherapy in Breast Cancer Patients after Breast-Conserving Surgery. American Society for Radiation Oncology (ASTRO) 61th Annual Meeting, September 11 - 15, 2017, Chicago, USA.
  • Gultekin M, Guler OC, Yuce Sari S, Akkus Yildirim B, Mustafayev TZ, Atalar B, Bolukbasi Y, Onal HC, Celik H, Yuce K, Ayhan A, Yildiz F.: Validation of the ESMO-ESGO-ESTRO Consensus Conference Risk Grouping in Turkish Endometrial Cancer Patients Treated with Comprehensive Surgical Staging. American Society for Radiation Oncology (ASTRO) 61th Annual Meeting, September 11 - 15, 2017, Chicago, USA.
  • Kose F, Alemdaroglu S, Mertsoylu H, Besen A, Guler OC, Simsek S, Erbay G, Onal C, Celik H.: Clinical characteristics of relapsed ovarian cancer patients with striking response to the bevacizumab at first relapse. Xth Eurasian Hematology Oncology Congress, 8-11 October 2019, Istanbul, Turkey.
  • Onal C, Torun, Guler OC, Reyhan M, Akkus Yildrim B, Yapar AF.: Is there a correlation between Gleason score and maximum standardized uptake value in locally advanced prostate cancer patients?. ASCO 2019 Genitourinary Cancers Symposium, 14 – 16 February 2019, San Fransisco, USA.
  • Yildirim B, Onal C, Kose F, Oymak E, Sedef AM, Besen AA, Aksoy S, Guler OC, Sumbul AT, Mertsoylu H, Ozyigit G.: The outcome of loco-regional radiotherapy in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate. ASCO 2019 Genitourinary Cancers Symposium, 14 – 16 February 2019, San Fransisco, USA.
  • Onal C, Sedef AM, Kose F, Oymak E, Guler OC, Sumbul AT, Aksoy S, Akkus Yildrim B, Besen AA, Mullaoglu S, Mertsoylu H, Ozyigit G.: The hematologic parameters in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate. ASCO 2019 Genitourinary Cancers Symposium, 14 – 16 February 2019, San Fransisco, USA.
  • Onal C, Efe E, Akkus Yildirim B, Guler OC.: Dosimetric Comparison of Simultaneous-İntegrated boost and Sequential boost with VMAT or Helical Tomotherapy in Breast Cancer Patients after Breast-Conserving Surgery. American Society for Radiation Oncology (ASTRO) 61th Annual Meeting, September 11 - 15, 2017, Chicago, USA.
  • Guler OC, Yildirim BA, Ozyilkan O, Onal C.: Treatment outcomes of breast cancer liver metastasis with stereotactic radiotherapy. San Antonio Breast Cancer Symposium. 10-14 December 2019, San Antonio, USA.
  • Onal C, Guler OC, Torun N, Reyhan M, Yapar AF.: The effect of androgen deprivation therapy on 68GA-PSMA-tracer uptake in nonmetastatic prostate cancer patients. ASCO 2020 Genitourinary Cancers Symposium, 13 – 15 February 2020, San Fransisco, USA.
  • Guler OC, Erbay G, Torun N, Onal C.: The Role of 68Ga-PSMA-PET/CT and Diffusion Weighted-MRI in Lymph Node Staging in Prostate Cancer Patients Treated with Definitive Radiotherapy. American Society for Radiation Oncology (ASTRO). 24 - 28 October 2020, Virtual Meeting.
  • Guler OC, Akkus Yildirim B, Onal C.: The İmpact of Tumor Volume in Breast Cancer Liver Metastasis Patients Treated with Stereotactic Radiotherapy - Does Size Matter?. American Society for Radiation Oncology (ASTRO). 24 - 28 October 2020, Virtual Meeting.
  • Onal C, Demiral AN, Atalar B, Yalman D, Dagoglu N, Hurmuz P, Erpolat P, Akyurek S, Karabulut Gul S, Berber T, Guler OC, Umay C, Sert F, Saglam EK, Eray K, Duru Birgi S, Yaprak G.: National, Observational, Multicentric Retrospective Study to Understand Treatment Patterns, Patient Journey and Characteristics with Stage III Non-Small Cell Lung Cancer Patients in Turkey: STONE Trial. American Society for Radiation Oncology (ASTRO). 24 - 28 October 2020, Virtual Meeting.
  • Onal C, Ozyigit G, Oymak E, Guler OC, Hurmuz P, Tilki B, Torun N, Tuncel M, Reyhan M, Caglar M, Yapar AF, Akyol F.: Interpreting Clinical Parameters and Nomograms for Predicting Lymph Node Metastasis Detected with 68Ga-PSMAPET/CT in prostate cancer patients. American Society for Radiation Oncology (ASTRO). 24 - 28 October 2020, Virtual Meeting.
  • Güler OC, Sari SY, Gultekin M, Yildirim BA, Ozyilkan O, Yildiz F, Onal C.: Treatment outcomes of breast cancer lung metastasis treated with stereotactic body radiotherapy. ESTRO 2020, 30 November - 01 December 2020, Online congress.
  • Güler OC, Yildirim BA, Onal C.: Treatment outcomes of liver metastasis treated with stereotactic body radiotherapy. ESTRO 2020, 30 November - 01 December 2020, Online congress.
  • Onal C, Guler OC, Torun N, Reyhan M.: The significance of nomograms for predicting node metastasis in 68Ga-PSMA-PET/CT in prostate cancer. ESTRO 2020, 30 November - 01 December 2020, Online congress.
  • Güler OC, Hurmuz P, Tilki B, Ozyigit G, Yildirim BA, Akyol F, Onal C.: SBRT in patients with oligometastatic renal cell carcinoma in the era of immunotherapy. ESTRO 2020, 30 November - 01 December 2020, Online congress.
  • Onal C, Bozca R, Dolek Y, Guler OC, Arslan G.: Incidental testicular doses during volumetricmodulated ARC radiotherapy in prostate cancer patients. ESTRO 2020, 30 November - 01 December 2020, Online congress.
  • Onal C, Yuce Sari S, Yavas G, Guler OC, Yigit E, Oymak E, Gultekin M, Yildiz F.: The impact of lymph node ratio in patients with stage IIIC endometrial carcinoma. . ESTRO 2021, 27 August 2021 - 31 August 2021 Madrid, Spain Onsite/Online.
  • Onal C, Ozyigit G, Oymak E, Guler OC, Hurmuz P, Tilki B, Reyhan M, Tuncel M, Akyol F.: Clinical parameters and nomograms for predicting lymphnode metastasis detected with 68Ga-PSMA-PET/CT. ESTRO 2021, 27 August 2021 - 31 August 2021 Madrid, Spain Onsite/Online.
  • Oymak E, Güler OC, Önal C.: Significance of liver metastasis volume in breast cancer treated with stereotactic body radiotherapy. ESTRO 2021, 27 August 2021 - 31 August 2021 Madrid, Spain Onsite/Online.
  • Onal C, Gultekin M, Yavas G, Oymak E, Yuce Sari S, Guler OC, Yigit E, Yildiz F.: Albumin-to-alkaline phosphatase ratio is not a predictor of survival in cervical cancer patients. . ESTRO 2021, 27 August 2021 - 31 August 2021 Madrid, Spain Onsite/Online.
  • Onal C, Oymak E, Guler OC.: The prognostic significance of the albumin and globulin levels in cervical cancer patients. ESTRO 2021, 27 August 2021 - 31 August 2021 Madrid, Spain Onsite/Online.
  • Onal C, Ozyigit G, Oymak E, Guler OC, Tilki B, Hurmuz P, Akyol F.: Stereotactic Radiotherapy to Oligoprogressive Lesions Detected With 68Ga-PSMA-PET/CT in Castration-Resistant Prostate Cancer Patients. American Society for Radiation Oncology (ASTRO) 63. 24 - 27 October 2020, Chicago, USA.
  • Onal C, Kose F, Ozyigit G, Aksoy S, Oymak E, Muallaoglu S, Guler OC, Tilki B, Hürmüz P, Akyol F.: Stereotactic Body Radiotherapy for Oligoprogressive Lesions in Metastatic Castration-Resistant Prostate Cancer Patients During Abiraterone/Enzalutamide Treatment. American Society for Radiation Oncology (ASTRO) 63. 24 - 27 October 2020, Chicago, USA.
  • Onal C, Guler OC, Reyhan M, Yapar AF.: Long-Term Outcomes of Cervical Cancer Patients With Complete Metabolic Response After Definitive Chemoradiotherapy. American Society for Radiation Oncology (ASTRO) 63. 24 - 27 October 2020, Chicago, USA.
  • Guler OC, Yuce Sari S, Gültekin M, Yıldız F, Onal C.: The clinical outcomes of breast cancer lung metastasis treated with stereotactic body radiotherapy. ESTRO 2022, 6 – 10 May 2022 Copenhagen, Denmark Onsite/Online.
  • Onal C, Guler OC, Oymak E, Torun N, Reyhan M.: Response evaluation with 68GA-PSMA-PET/CT in prostate cancer patients treated with radiotherapy. ESTRO 2022, 6 – 10 May 2022 Copenhagen, Denmark Onsite/Online.
  • Guler OC, Hurmuz P, Ozyigit G, Onal C.: SBRT in patients with oligometastatic renal cell carcinoma: A multi-institutional analysis. ESTRO 2022, 6 – 10 May 2022 Copenhagen, Denmark Onsite/Online.
  • Guler OC, Oymak E, Onal C.: The Dosimetric Analysis & Clinical Outcomes of Contiguous Vertebrae SBRT in Oligometastatic Patients. ESTRO 2022, 6 – 10 May 2022 Copenhagen, Denmark Onsite/Online.
  • Sutera P, Deek M, Guler OC, Hurmuz P, Reyhan M, Rowe SP, Hrinivich W, Ren L, Kiess AP, Song DY, Oymak EO, Pienta KJ, Pomper M, Feng FY, Ozyigit G, Tran PT, Phillips R, Onal HC.: Prostate-specific membrane antigen PET response associates with radiographic progression-free survival following stereotactic ablative radiation therapy in oligometastatic castration-sensitive prostate cancer. ASCO 2022 Annual Symposium, 3 – 7 June 2017, Chicago, USA.
  • Guler OC, Oymak E, Yazici G, Ozkaya Akagunduz O, Cetinayak O, Erpolat P, Aksoy A, Duzova M, Akkus Yildirim B, Kurt M, Canyılmaz E, Akyurek S, Atalar B, Yavas G, Oksuz DC, Saglam EK, Karakoyun Celik O, Cengiz M, Onal C.: The Treatment Outcomes of Patients with Cervical Esophageal Carcinoma Undergoing Definitive Chemoradiotherapy: A Multi-Institutional Analysis TROD 01-005. American Society for Radiation Oncology (ASTRO) 64. 23 - 26 October 2022, San Antonio, USA.
  • Guler OC, Hurmuz P, Atalar B, Yukselen Guney Y, Saglam EK, Akyurek S, Bolukbasi Y, Gural Z, Tugrul F, Korcum AF, Sen CA, Akkus Yildirim B, Oksuz DC, Karakoyun Celik O, Kurt M, Guzeloz Z, Yavas G, Ozyigit G, Aksu MG, Onal C.: The Treatment Outcomes of Oligometastatic Colorectal Cancer Patients Treated with Stereotactic Body Radiation Therapy: A Multi-Institutional Analysis TROD 02-008. American Society for Radiation Oncology (ASTRO) 64. 23 - 26 October 2022, San Antonio, USA.
  • Sutera P, Deek MP, Guler OC, Hurmuz P, Reyhan M, Rowe S, Hrinivich WT, Ren L, Song D, Kiess AP, Oymak E, Pienta K, Pomper MG, Feng FY, Ozyigit G, Tran PT, Phillips R, Onal C.: Prostate-Specific Membrane Antigen PET Response Associates with Metastasis-Free Survival Following Stereotactic Ablative Radiation Therapy in Oligometastatic Castration-Sensitive Prostate Cancer. American Society for Radiation Oncology (ASTRO) 64. 23 - 26 October 2022, San Antonio, USA.
  • Onal C, Guler OC, Erbay G, Oymak E, Yavas C, Yavas G.: The Outcomes of Definitive Radiotherapy in Patients with Prostate Cancer Using Simultaneous Integrated Boost Technique. American Society for Radiation Oncology (ASTRO) 64. 23 - 26 October 2022, San Antonio, USA.
  • Onal C, Erbay G, Guler OC, Akkus Yildirim B, Arslan G.: The Feasibility and Toxicity Analysis of Simultaneous Integrated Boost of 86 Gy to Intraprostatic Tumor Delivered in 39 Fractions. American Society for Radiation Oncology (ASTRO) 64. 23 - 26 October 2022, San Antonio, USA.
  • Onal C, Guler OC, Hurmuz P, Yavas G, Tilki B, Oymak E, Yavas C, Ozyigit G.: Bone Only Oligometastatic Renal Cell Carcinoma Patients Treated with Stereotactic Body Radiotherapy: A Multi-Institutional Study. American Society for Radiation Oncology (ASTRO) 64. 23 - 26 October 2022, San Antonio, USA.
  • Oymak E, Demircan V, Senyurek S, Yavas G, Guler OC, Bolukbasi Y, Erpolat P, Onal C.: The Effect of the Time Interval between Temozolomide and Radiotherapy in Adjuvant High-Grade Glioma Treatment. American Society for Radiation Oncology (ASTRO) 64. 23 - 27 October 2020, San Antonio, USA. (ASTRO) 64. 23 - 26 October 2022, San Antonio, USA.

Değerlendirmeler

Değerlendir

Değerlendirmeler

Değerlendir

Hasta Soruları

Randevu Alın

Bu uzmanın online randevu alabileceğiniz bir takvimi bulunmuyor.

Randevu takvimi talep edin

Bu Siz Misiniz?

Profildeki bir bilginin yanlış veya güncel olmadığını düşünüyorsanız bize bildirin. Talebiniz moderatörlerimiz tarafından incelenecektir.

Sahiplen Düzeltme İste